

PATENT
APPLICATION

Group Art Unit	1654	
Examiner:	Delacroix-Muirhead	
Atty. Dkt.	PMS 235299	960018PH/De
	M#	Client Ref

(Our Deposit Account No. 03-3975)

(Our Order No.	11468	235299
	C#	

Asst. Commissioner of Patents
Washington, D.C. 20231

JUN 4 1999

REPLY/AMENDMENT/LETTER

**MATRIX CUSTOMER
SERVICE CENTER**

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. "Small Entity" statement(s) filed <input type="checkbox"/> previously <input type="checkbox"/> herewith (No.)		Claims remaining after amendment		Highest number previously paid for		Present Extra		Large/Small Entity		Additional Fee		Fee Code	
2. Total Effective Claims		17		**minus 20		0		x \$18/\$9 =		+ 0		103/203	
3. Independent Claims		2		***minus 3		0		x \$78/\$39 =		+ 0		102/202	
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application).....add								+ \$260/\$130 =		+ 0		104/204	
5. Original due Date: JUNE 3, 1999				<input type="checkbox"/> NONE									
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached				(1 mo)		\$110/\$55 =		+ 0				115/215	
				(2 mos)		\$380/\$190 =						116/216	
				(3 mos)		\$870/\$435 =						117/217	
7. Enter any previous extension fee paid since above original due date and subtract								-					
8. Extension Fee Attached										+ 0			
9. If Terminal Disclaimer attached, add Rule 20(d) official fee								+ \$/\$ =		+ 0		148/248	
10. If IDS attached requires Official Fee,add or if Rule 97(d) Petitionadd								+ \$ =		+ 0		126	
								+ \$ =				122	
11. After-Final Request Fee per rules 129(a) and 17(r)								+ \$760/380 =		+ 0		146/246	
12. No. of additional inventions for examination per Rule 129(b)								x \$760/380 ea =		+ 0		149/249	
13. Petition fee for										+ 0			
14. TOTAL FEE ENCLOSED =										\$0			

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown in the heading hereof, for which purpose a duplicate copy of this sheet is attached.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Reg. No. 36830

Fax: (202) 822-0944
Tel: (202) 861-3063

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of

BOUCHARD, et al.

Appln. No.: 08/786,937

Filed: January 22, 1997



Group Art Unit: 1801

Examiner: Delacroix-Muirhead

13/C
H.G.J
6/8/99

FOR: LHRH-ANTAGONISTS IN THE
TREATMENT OF FERTILITY DISORDERS

* * * * *

June 3, 1999

AMENDMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

In response to the Official Action issued March 3, 1999, please enter the
following amendments and consider the following remarks.

IN THE CLAIMS:

Amend the claims as follows:

18. (Twice amended) The method according to claim 15 wherein after [the]
suppression of endogenous
inhibition of the action of natural LH caused by the LH-RH Antagonist, [the] follicle
growth
development is not externally stimulated but maintained by [endogenous]
endogenous gonadotropins.

20. (Twice amended) The method according to claim 16 wherein Cetorelix
is administered subcutaneously in an amount of about 0.25 mg [or higher] to 1 mg
per day during a multiple dosing posology.